相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity
Hind Rafei et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review
Parham Jabbarzadeh Kaboli et al.
CURRENT MEDICINAL CHEMISTRY (2020)
The Outcome of Ex Vivo TIL Expansion Is Highly Influenced by Spatial Heterogeneity of the Tumor T-Cell Repertoire and Differences in Intrinsic In Vitro Growth Capacity between T-Cell Clones
Isabel C. Poschke et al.
CLINICAL CANCER RESEARCH (2020)
Highly Efficient Generation of Transgenically Augmented CAR NK Cells Overexpressing CXCR4
Arezoo Jamali et al.
FRONTIERS IN IMMUNOLOGY (2020)
Inducible Caspase9-mediated suicide gene for MSC-based cancer gene therapy
Filippo Rossignoli et al.
CANCER GENE THERAPY (2019)
Antitumor effects of berberine against EGFR, ERK1/2, P38 and AKT in MDA-MB231 and MCF-7 breast cancer cells using molecular modelling and in vitro study
Parham Jabbarzadeh Kaboli et al.
PHARMACOLOGICAL REPORTS (2019)
Genetically engineered CAR NK cells display selective cytotoxicity against FLT3-positive B-ALL and inhibit in vivo leukemia growth
Sarah Oelsner et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes
Yanheng Wu et al.
NANOMEDICINE (2019)
The Emerging World of TCR-T Cell Trials Against Cancer: A Systematic Review
Jianxiang Zhang et al.
TECHNOLOGY IN CANCER RESEARCH & TREATMENT (2019)
Chimeric Antigen Receptors for T-Cell Malignancies
Lauren D. Scherer et al.
FRONTIERS IN ONCOLOGY (2019)
Synthetic T cell receptor-based lymphocytes for cancer therapy
Daniel Getts et al.
ADVANCED DRUG DELIVERY REVIEWS (2019)
Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432
F. Wang et al.
ANNALS OF ONCOLOGY (2019)
Induced pluripotent stem cells as a novel cancer vaccine
Lin Wang et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2019)
Engineering switchable and programmable universal CARs for CAR T therapy
Delong Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Synthetic TRuC receptors engaging the complete T cell receptor for potent anti-tumor response
Patrick A. Baeuerle et al.
NATURE COMMUNICATIONS (2019)
A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients
Daan P. Hurkmans et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
T cell engineering for adoptive T cell therapy: safety and receptor avidity
Elvira D'Ippolito et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Robo1-specific CAR-NK Immunotherapy Enhances Efficacy of 125I Seed Brachytherapy in an Orthotopic Mouse Model of Human Pancreatic Carcinoma
Ning Xia et al.
ANTICANCER RESEARCH (2019)
Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma
Yuexin Xu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2019)
Targeting PD-1 in cancer: Biological insights with a focus on breast cancer
Cinzia Solinas et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2019)
m1A Regulated Genes Modulate PI3K/AKT/mTOR and ErbB Pathways in Gastrointestinal Cancer
Yueshui Zhao et al.
TRANSLATIONAL ONCOLOGY (2019)
Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment
A. Pawlowska et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2019)
Improving TCR affinity on 293T cells
Rieko Ohta et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2019)
Targeting cancers through TCR-peptide/MHC interactions
Qinghua He et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2019)
Concise Review: Modulating Cancer Immunity with Hematopoietic Stem and Progenitor Cells
Tyler J. Wildes et al.
STEM CELLS (2019)
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
E. Liu et al.
LEUKEMIA (2018)
Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo
Nigel G. Kooreman et al.
CELL STEM CELL (2018)
ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression
Huanling Zhang et al.
IMMUNOLOGY (2018)
Monomeric TCRs drive T cell antigen recognition
Mario Brameshuber et al.
NATURE IMMUNOLOGY (2018)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Molecular modeling, dynamics simulations, and binding efficiency of berberine derivatives: A new group of RAF inhibitors for cancer treatment
Parham Jabbarzadeh Kaboli et al.
PLOS ONE (2018)
Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity
A. J. Davenport et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2018)
CAR T cell immunotherapy for human cancer
Carl H. June et al.
SCIENCE (2018)
Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy
Huang Zhu et al.
STEM CELLS (2018)
Increased diversity with reduced diversity evenness of tumor infiltrating T-cells for the successful cancer immunotherapy
Akihiro Hosoi et al.
SCIENTIFIC REPORTS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Non-viral suicide gene therapy in cervical, oral and pharyngeal carcinoma cells with CMV- and EEV-plasmids
Nejat Duzgunes et al.
JOURNAL OF GENE MEDICINE (2018)
An approved in vitro approach to preclinical safety and efficacy evaluation of engineered T cell receptor anti-CD3 bispecific (ImmTAC) molecules
Jane Harper et al.
PLOS ONE (2018)
The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity
Christopher W. Helsen et al.
NATURE COMMUNICATIONS (2018)
Manual small incision cataract surgery: Experience of a regional eye care service in Togo (vol 41, pg 255, 2018)
K. B. Nonon Saa et al.
JOURNAL FRANCAIS D OPHTALMOLOGIE (2018)
Linking a cell-division gene and a suicide gene to define and improve cell therapy safety
Qin Liang et al.
NATURE (2018)
Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
Michael M. Boyiadzis et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Cell Biology of T Cell Receptor Expression and Regulation
Andres Alcover et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 36 (2018)
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model
Benjamin Y. Jin et al.
JCI INSIGHT (2018)
Activation induced cell death (AICD) of human melanoma antigen-specific TCR engineered CD8 T cells involves JNK, Bim and p53
Arvind Chhabra et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
The Allostery Model of TCR Regulation
Wolfgang W. A. Schamel et al.
JOURNAL OF IMMUNOLOGY (2017)
Polyfunctional response by ImmTAC (IMCgp100) redirected CD8+ and CD4+ T cells
Caroline Boudousquie et al.
IMMUNOLOGY (2017)
Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review
Faiz Anwer et al.
IMMUNOTHERAPY (2017)
Occurrence of rheumatic symptoms in celiac disease: A meta-analysis: Comment on the article Osteoarticular manifestations of celiac disease and non-celiac gluten hypersensitivity by Dos Santos and Liote. Joint Bone Spine 2016, doi:10.1016/j.jbspin.2016.09.007
Coline Daron et al.
JOINT BONE SPINE (2017)
The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy
Felipe Bedoya et al.
MOLECULAR THERAPY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Caspase-9: structure, mechanisms and clinical application
Ping Li et al.
ONCOTARGET (2017)
Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies
Baixin Ye et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2017)
PD-1/PD-L1 and immunotherapy for pancreatic cancer
Mengyu Feng et al.
CANCER LETTERS (2017)
Targeting neoantigens to augment antitumour immunity (vol 17, pg 209, 2017)
Mark Yarchoan et al.
NATURE REVIEWS CANCER (2017)
A common anti-cytomegalovirus drug, ganciclovir, inhibits HIV-1 replication in human tissues ex vivo
Christophe Vanpouille et al.
AIDS (2017)
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
Rebecca A. Gardner et al.
BLOOD (2017)
T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells
Hiroaki Ikeda
INTERNATIONAL IMMUNOLOGY (2016)
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
Daniel T. Harris et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2016)
An MHC-restricted antibody-based chimeric antigen receptor requires TCR-like affinity to maintain antigen specificity
Marcela V. Maus et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
New Insights into How Trafficking Regulates T Cell Receptor Signaling
Jieqiong Lou et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2016)
Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation
Xiaoou Zhou et al.
BLOOD (2015)
T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells
M. P. Tan et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2015)
Adoptive T-cell therapy for cancer: The era of engineered T cells
Chiara Bonini et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2015)
ImmTACs for targeted cancer therapy: Why, what, how, and which
Joanne Oates et al.
MOLECULAR IMMUNOLOGY (2015)
Adoptive cell transfer as personalized immunotherapy for human cancer
Steven A. Rosenberg et al.
SCIENCE (2015)
CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells
Jianfeng Han et al.
SCIENTIFIC REPORTS (2015)
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene
Xiaoou Zhou et al.
BLOOD (2014)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Accumulation of Dynamic Catch Bonds between TCR and Agonist Peptide-MHC Triggers T Cell Signaling
Baoyu Liu et al.
CELL (2014)
Suicide genes: monitoring cells in patients with a safety switch
Linda G. Eissenberg et al.
FRONTIERS IN PHARMACOLOGY (2014)
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
Gerald P. Linette et al.
BLOOD (2013)
Bi-specific TCR-anti CD3 redirected T-cell targeting of NY-ESO-1-and LAGE-1-positive tumors
Emmet McCormack et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
A Single Peptide-Major Histocompatibility Complex Ligand Triggers Digital Cytokine Secretion in CD4+ T Cells
Jun Huang et al.
IMMUNITY (2013)
Production and First-in-Man Use of T Cells Engineered to Express a HSVTK-CD34 Sort-Suicide Gene
Hong Zhan et al.
PLOS ONE (2013)
Monoclonal TCR-redirected tumor cell killing
Nathaniel Liddy et al.
NATURE MEDICINE (2012)
A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell engagers (BiTEs)
Jennifer D. Stone et al.
ONCOIMMUNOLOGY (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
Renier J. Brentjens et al.
BLOOD (2011)
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Antonio Di Stasi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
Richard A. Morgan et al.
MOLECULAR THERAPY (2010)
Complete but curtailed T-cell response to very low-affinity antigen
Dietmar Zehn et al.
NATURE (2009)
The role of TNF superfamily members in T-cell function and diseases
Michael Croft
NATURE REVIEWS IMMUNOLOGY (2009)
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells
Brian G. Till et al.
BLOOD (2008)
Requirements for effective antitumor responses of TCR transduced T cells
Moniek A. de Witte et al.
JOURNAL OF IMMUNOLOGY (2008)
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
Martin A. Pule et al.
NATURE MEDICINE (2008)
Coexistence of multivalent and monovalent TCRs explains high sensitivity and wide range of response
WWA Schamel et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Crystal structure of a human CD-ε/δ dimer in complex with a UCHT1 single-chain antibody fragment
KL Arnett et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
分享论文
